- Current report filing (8-K)

---

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  05/20/2010

 

DARA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Commission File Number:  0-19140

 

Delaware		04-3216862
(State or other jurisdiction of		(IRS Employer
incorporation)		Identification No.)

 

8601 Six Forks Road, Suite 160

Raleigh, North Carolina 27615

(Address of principal executive offices, including zip code)

 

[phone]

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

 

Item 8.01.    Other Events

 

On May 20, 2010 and May 24, 2010, Richard A. Franco, Sr., R. Ph., the Chairman and President of DARA BioSciences, Inc. (the "Company"), purchased a total of 3,000 shares of the Company's common stock in open market purchases.

 

---

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

								DARA BIOSCIENCES, INC.
Date: May 24, 2010						By:		/s/    Richard A. Franco, Sr., R. Ph
								Richard A. Franco, Sr., R. Ph
								Chairman and Chief Executive Officer